Compare Abbott India with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs BIOCON - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA BIOCON ABBOTT INDIA/
BIOCON
 
P/E (TTM) x 47.3 35.1 134.8% View Chart
P/BV x 15.5 4.4 347.7% View Chart
Dividend Yield % 0.4 0.2 201.0%  

Financials

 ABBOTT INDIA   BIOCON
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
BIOCON
Mar-19
ABBOTT INDIA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs8,834707 1,249.0%   
Low Rs5,458554 985.5%   
Sales per share (Unadj.) Rs1,731.191.9 1,883.5%  
Earnings per share (Unadj.) Rs211.916.7 1,268.2%  
Cash flow per share (Unadj.) Rs219.924.2 909.6%  
Dividends per share (Unadj.) Rs65.001.00 6,500.0%  
Dividend yield (eoy) %0.90.2 573.6%  
Book value per share (Unadj.) Rs945.2101.6 930.0%  
Shares outstanding (eoy) m21.25600.00 3.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.16.9 60.2%   
Avg P/E ratio x33.737.7 89.4%  
P/CF ratio (eoy) x32.526.1 124.6%  
Price / Book Value ratio x7.66.2 121.9%  
Dividend payout %30.76.0 512.5%   
Avg Mkt Cap Rs m151,848378,330 40.1%   
No. of employees `0003.56.1 56.8%   
Total wages/salary Rs m4,35611,653 37.4%   
Avg. sales/employee Rs Th10,555.58,994.3 117.4%   
Avg. wages/employee Rs Th1,249.91,900.7 65.8%   
Avg. net profit/employee Rs Th1,292.21,635.3 79.0%   
INCOME DATA
Net Sales Rs m36,78655,144 66.7%  
Other income Rs m1,1331,444 78.5%   
Total revenues Rs m37,91956,588 67.0%   
Gross profit Rs m6,04715,883 38.1%  
Depreciation Rs m1694,478 3.8%   
Interest Rs m23709 3.2%   
Profit before tax Rs m6,98912,140 57.6%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4852,123 117.1%   
Profit after tax Rs m4,50310,026 44.9%  
Gross profit margin %16.428.8 57.1%  
Effective tax rate %35.617.5 203.4%   
Net profit margin %12.218.2 67.3%  
BALANCE SHEET DATA
Current assets Rs m27,61048,228 57.2%   
Current liabilities Rs m8,56930,376 28.2%   
Net working cap to sales %51.832.4 159.9%  
Current ratio x3.21.6 202.9%  
Inventory Days Days6068 88.2%  
Debtors Days Days2786 32.0%  
Net fixed assets Rs m1,05764,130 1.6%   
Share capital Rs m2133,000 7.1%   
"Free" reserves Rs m19,87357,980 34.3%   
Net worth Rs m20,08660,980 32.9%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m29,409121,924 24.1%  
Interest coverage x311.618.1 1,719.4%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.5 276.6%   
Return on assets %15.48.8 174.8%  
Return on equity %22.416.4 136.4%  
Return on capital %34.916.8 208.3%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m36915,506 2.4%   
Fx outflow Rs m4,91810,399 47.3%   
Net fx Rs m-4,5495,107 -89.1%   
CASH FLOW
From Operations Rs m4,99111,546 43.2%  
From Investments Rs m-2,570-7,138 36.0%  
From Financial Activity Rs m-1,428-2,417 59.1%  
Net Cashflow Rs m9932,103 47.2%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 7.9 8.4 94.0%  
FIIs % 0.1 10.7 0.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 19.9 85.9%  
Shareholders   18,270 109,995 16.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Rallied 834 Points Today(Closing)

After staging a gap-up opening, Indian share markets extended gains as the session progressed and rallied nearly 2%, boosted by realty and finance stocks.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 19, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS